Sign up Australia
Proactive Investors - Run By Investors For Investors

AusCann Group Holdings welcomes medical cannabis legislation

AusCann is trading up 115% to $0.43 from its February 2017 ASX debut at $0.20.
Australian parliament house of representatives
The bill has now been introduced to the House of Representatives for debate

AusCann Group Holdings (ASX:AC8) welcomes the passing of the Medicinal Cannabis Legislation Amendment (Securing Patient Access) Bill 2017 in the Senate yesterday.

The bill was introduced to expand upon the ability of terminally ill patients to access cannabinoid medicines.

Currently, certain terminally ill patients can only access cannabinoid medicines that are imported on a patient by patient basis.

This bill will enable these terminally ill patients to access cannabinoid medicines that are produced by AusCann in Australia as well as those medicines being imported by AusCann.

Through its strategic partnership with Canopy Growth Corporation, AusCann is able to import cannabinoid medicines that are already being used to treat patients in Canada.

Elaine Darby, managing director, commented

“We welcome the introduction of any measures that further enhances the ability of terminally ill patients to access medications their doctors believe can assist them.

“We look forward to being able to supply these Australian patients with high quality, cost-effective, clinically validated medications that have been produced in Australia.”

Next steps for the bill

The bill has now progressed and has been introduced to the House of Representatives for debate.

AusCann is closely monitoring the progress of this bill and looks forward to the pending legislative change being implemented.

In the interim, AusCann’s medical liaison managers are actively working with Australian doctors that are able to prescribe AusCann’s cannabinoid medicines under current legislation.

WATCH NOW: AusCann Group Holdings positioned to be a leading supplier of Australian cannabinoid

READ NOW: AusCann Group Holdings Ltd granted Australian medicinal cannabis manufacturing licence

View full AC8 profile View Profile

AusCann Group Holdings Ltd Timeline

Related Articles

Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
picture of cannabis plants
March 24 2018
Control of the supply chain offers operational advantages and financial benefits.
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use